Differentiation Effects by the Combination of Spheroid Formation and Sodium Butyrate Treatment in Human Hepatoblastoma Cell Line (Hep G2): A Possible Cell Source for Hybrid Artificial Liver
Free accessResearch articleFirst published online November, 2005
Differentiation Effects by the Combination of Spheroid Formation and Sodium Butyrate Treatment in Human Hepatoblastoma Cell Line (Hep G2): A Possible Cell Source for Hybrid Artificial Liver
The aim of this study was to investigate the feasibility of human hepatoblastoma cell line (Hep G2), which differentiates by spheroid formation, and treatment with sodium butyrate (SB) as a cell source for hybrid artificial liver (HAL). Hep G2 spontaneously formed spheroids in polyurethane foam (PUF) within 3 days of culture and restored weak ammonia removal activity. Treatment with SB, which is a histone deacetylase inhibitor, further increased the ammonia removal activity of Hep G2 spheroids in a concentration-dependent manner. The activation of ornithine transcarbamylase—a urea cycle enzyme—was significantly related to the upregulation of ammonia removal by spheroid formation, but scarcely contributed to the further upregulation following SB treatment. In contrast with ammonia removal, treatment with SB reduced the albumin secretion of Hep G2 spheroids in a concentration-dependent manner. In the PUF-HAL module in a circulation culture, the ammonia removal rate and albumin secretion rate (per unit volume of the module) of Hep G2 spheroids treated with 5 mM SB were almost the same as those of primary porcine hepatocyte spheroids. These results suggest that simultaneous use of spheroid formation and SB treatment in Hep G2 is beneficial in enhancing the functions of human hepatocytes with potential applications in regenerative medicine and drug screening.
ClemmesenJ. O.LarsenF. S.KondrupJ.HansenB. A.OttP.Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration.Hepatology29: 648–653; 1999.
4.
CummingsJ. H.PomareE. W.BranchW. J.NaylorC. P.MacfarlaneG. T.Short chain fatty acids in human large intestine, portal, hepatic and venous blood.Gut28: 1221–1227; 1987.
5.
CurranR. D.FerrariF. K.KispertP. H.StadlerJ.StuehrD. J.SimmonsR. L.BilliarT. R.Nitric oxide and nitric oxide-generating compounds inhibit hepatocyte protein synthesis.FASEB J.5: 2085–2092; 1991.
6.
DavieJ. R.Inhibition of histone deacetylase activity by butyrate.J. Nutr.133: 2485S–2493S; 2003.
7.
DemetriouA. A.BrownR.S.Jr.BusuttilR. W.FairJ.McGuireB. M.RosenthalP.Am EschJ. S.IILerutJ.NybergS. L.SalizzoniM.FaganE. A.de HemptinneB.BroelschC. E.MuracaM.SalmeronJ. M.RabkinJ. M.MetselaarH. J.PrattD.De La MataM.McChesneyL. P.EversonG. T.LavinP. T.StevensA. C.PitkinZ.SolomonB. A.Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.Ann. Surg.239: 660–667; 2004.
8.
EnosawaS.SuzukiS.KakefudaT.AmemiyaH.Examination of 7-ethoxycoumarin deethylation and ammonia removal activities in 31 hepatocyte cell line.Cell Transplant.5: S39–S40; 1996.
9.
FukudaJ.OkamuraK.NakazawaK.IjimaH.YamashitaY.ShimadaM.ShirabeK.TsujitaE.SugimachiK.FunatsuK.Efficacy of a polyurethane foam/spheroid artificial liver by using human hepatoblastoma cell line (Hep G2).Cell Transplant.12: 51–58; 2003.
10.
FukudaJ.SakiyamaR.NakazawaK.IjimaH.YamashitaY.ShimadaM.ShirabeK.TsujitaE.SugimachiK.FunatsuK.Mass preparation of primary porcine hepatocytes and the design of a hybrid artificial liver module using spheroid culture for a clinical trial.Int. J. Artif. Organs24: 799–806; 2001.
11.
FunatsuK.NakazawaK.Novel hybrid artificial liver using hepatocyte organoids.Int. J. Artif. Organs25: 77–82; 2002.
12.
GebhardtR.MeckeD.Permissive effect of dexamethasone on glucagon induction of urea-cycle enzymes in peri-fused primary monolayer cultures of rat hepatocytes.Eur. J. Biochem.97: 29–35; 1979.
13.
GionT.ShimadaM.ShirabeK.NakazawaK.IjimaH.MatsushitaT.FunatsuK.SugimachiK.Evaluation of a hybrid artificial liver using a polyurethane foam packed-bed culture system in dogs.J. Surg. Res.82: 131–136; 1999.
14.
GuoZ.YuanC.Wei-LaveryT.FangY.GarvinR. A.NishidaH. I.NishidaT.Secretion of phospholipid transfer protein by human hepatoma cell line, Hep G2, is enhanced by sodium butyrate.J. Nutr.129: 1984–1991; 1999.
15.
HodinR. A.MengS.ArcherS.TangR.Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT-29 cells.Cell Growth Differ.7: 647–653; 1996.
16.
HoshideR.MatsuuraT.SagaraY.KuboT.ShimadzuM.EndoF.MatsudaI.Prenatal monitoring in a family at high risk for ornithine transcarbamylase (OTC) deficiency: A new mutation of an A-to-C transversion in position +4 of intron 1 of the OTC gene that is likely to abolish enzyme activity.Am. J. Med. Genet.64: 459–464; 1996.
17.
IjimaH.MatsushitaT.NakazawaK.FujiiY.FunatsuK.Hepatocyte spheroids in polyurethane foams: Functional analysis and application for a hybrid artificial liver.Tissue Eng.4: 213–226; 1998.
18.
KimuraT.ChowdhuryS.TanakaT.ShimizuA.IwaseK.OyadomariS.GotohT.MatsuzakiH.MoriM.AkiraS.TakiguchiM.CCAAT/enhancer-binding protein beta is required for activation of genes for ornithine cycle enzymes by glucocorticoids and glucagon in primary-cultured hepatocytes.FEBS Lett.494: 105–111; 2001.
19.
NakazawaK.IjimaH.FukudaJ.SakiyamaR.YamashitaY.ShimadaM.ShirabeK.TsujitaE.SugimachiK.FunatsuK.Development of a hybrid artificial liver using polyurethane foam/hepatocyte spheroid culture in a preclinical pig experiment.Int. J. Artif. Organs25: 51–60; 2002.
20.
NatsukaS.AkiraS.NishioY.HashimotoS.SugitaT.IsshikiH.KishimotoT.Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6.Blood79: 460–466; 1992.
21.
NebesV. L.MorrisS.M.Jr.Regulation of messenger ribonucleic acid levels for five urea cycle enzymes in cultured rat hepatocytes.Requirements for cyclic adenosine monophosphate, glucocorticoids, and ongoing protein synthesis. Mol. Endocrinol.2: 444–451; 1988.
22.
NishiyoriA.TashiroH.KimuraA.AkagiK.YamamuraK.MoriM.TakiguchiM.Determination of tissue specificity of the enhancer by combinatorial operation of tissue-enriched transcription factors.Both HNF-4 and C/EBP beta are required for liver-specific activity of the ornithine transcarbamylase enhancer. J. Biol. Chem.269: 1323–1331; 1994.
23.
OhnoT.KimuraY.SugimuraK.SagawaA.JhodoS.AzumaI.Elevated gene expression of argininosuccinate synthetase in peripheral lymphocytes from systemic lupus erythematosus (SLE) patients.Autoimmunity13: 127–132; 1992.
24.
ParadisK.LangfordG.LongZ.HeneineW.SandstromP.SwitzerW. M.ChapmanL. E.LockeyC.OnionsD.; The XEN 111 Study Group; OttoE.Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue.Science285: 1236–1241; 1999.
25.
PatienceC.TakeuchiY.WeissR. A.Infection of human cells by an endogenous retrovirus of pigs.Nat. Med.3: 282–286; 1997.
26.
PiekarzR.BatesS.A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.Curr. Pharm. Des.10: 2289–2298; 2004.
27.
PitkinZ.SwitzerW.ChapmanL.An interim analysis of PERV infectivity in 74 patients treated with a bioartificial liver in a prospective, randomized, multicenter controlled trial.Hepatology34: 249A; 2001.
28.
SauerI. M.KardassisD.ZeillingerK.PascherA.GruenwaldA.PlessG.IrgangM.KraemerM.PuhlG.FrankJ.MullerA. R.SteinmullerT.DennerJ.NeuhausP.GerlachJ. C.Clinical extracorporeal hybrid liver support—phase I study with primary porcine liver cells.Xenotransplantation10: 460–469; 2003.
29.
SuaudL.JosephB.FormstecherP.LaineB.mRNA expression of HNF-4 isoforms and of HNF-1alpha/HNF-1beta variants and differentiation of human cell lines that mimic highly specialized phenotypes of intestinal epithelium.Biochem. Biophys. Res. Commun.235: 820–825; 1997.
30.
U.S. Public Health Service.U.S.Public Health Service guideline on infectious disease issues in xenotransplantation. Centers for Disease Control and Prevention. MMWR Recomm. Rep.50: 1–46; 2001.
31.
van de KerkhoveM. P.HoekstraR.ChamuleauR. A.van GulikT. M.Clinical application of bioartificial liver support systems.Ann. Surg.240: 216–230; 2004.
32.
van der LaanL. J.LockeyC.GriffethB. C.FrasierF. S.WilsonC. A.OnionsD. E.HeringB. J.LongZ.OttoE.TorbettB. E.SalomonD. R.Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice.Nature407: 90–94; 2000.
33.
van WezelA. L.Growth of cell-strains and primary cells on micro-carriers in homogeneous culture.Nature216: 64–65; 1967.
34.
WangL.SunJ.LiL.MearsD.HorvatM.SheilA. G.Comparison of porcine hepatocytes with human hepatoma (C3A) cells for use in a bioartificial liver support system.Cell Transplant.7: 459–468; 1998.
YamamotoH.FujimotoJ.OkamotoE.FuruyamaJ.TamaokiT.Hashimoto-TamaokiT.Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo.Int. J. Cancer76: 897–902; 1998.
37.
YamashitaY.ShimadaM.TsujitaE.TanakaS.IjimaH.NakazawaK.SakiyamaR.FukudaJ.UedaT.FunatsuK.SugimachiK.Polyurethane foam/spheroid culture system using human hepatoblastoma cell line (Hep G2) as a possible new hybrid artificial liver.Cell Transplant.10: 717–722; 2001.
38.
YaoH.SadoshimaS.FujiiK.KusudaK.IshitsukaT.TamakiK.FujishimaM.Cerebrospinal fluid lactate in patients with hepatic encephalopathy.Eur. Neurol.27: 182–187; 1987.
39.
YoonJ. H.LeeH. S.KimT. H.WooG. H.KimC. Y.Augmentation of urea-synthetic capacity by inhibition of nitric oxide synthesis in butyrate-induced differentiated human hepatocytes.FEBS Lett.474: 175–178; 2000.
40.
YoonJ. H.LeeH. V.LeeJ. S.ParkJ. B.KimC. Y.Development of a non-transformed human liver cell line with differentiated-hepatocyte and urea-synthetic functions: Applicable for bioartificial liver.Int. J. Artif. Organs22: 769–777; 1999.
